Simon Schwartz Navarro Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools. Institutions of which they are part Main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca Cap de Secció Bioquímica Cross-departmental services LinkedIn Twitter Orcid Simon Schwartz Navarro LinkedIn Twitter Orcid Institutions of which they are part Main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca Cap de Secció Bioquímica Cross-departmental services Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools.
Senior research of the clinical biochemistry - drug delivery and therapy group at VHIR and Strategy director of biobanking and biomodels at Vall d'hebron Campus. President of the European Society of Nanomedicine and Executive Board member of the International Society of Nanomedicine. Former director general of the Blood and Tissue Banc of Catalonia. Former director of CIBBIM-Nanomedicine. Former scientific associate director of CIBER-BBN and coordinator of technology transfer. Former director assistance of translational research at VHIR. H-index of 48, with more that 120 high impact publications, 19 transferred patents and several EU granted projects. Co-founder of 3 biotech companies (i.e, Bsure Medical ltd). Science Advisor of the European Nanomedicine Characterization Laboratory (EU-NCL). Member of the editorial Board of Precision Nanomedicine, J. Nanotechnology and of J. of Nanotheranostics. Former editorial Board member of Eur. J. Nanomedicine and Nanomedicine-NBM. Exper member of the nanomedicine group at EMA.
Projects Liberación dirigida de nanoconjugados de inhibidor de Alox5 contra células madre tumorales IP: Simon Schwartz Navarro Collaborators: Laura García Latorre, Diana Fernandes de Rafael Funding agency: Instituto de Salud Carlos III Funding: 171215 Reference: PI14/02079 Duration: 01/01/2015 - 31/12/2017 Sistemas de liberación farmacológica dirigidos contra células madre tumorales- prueba de concepto IP: Simon Schwartz Navarro Collaborators: Joaquin Seras Franzoso, Miriam Izquierdo Sans Funding agency: Asociación Española Contra el Cáncer Funding: 135000 Reference: 2014/AECC-AIO/SERAS Duration: 01/02/2015 - 31/01/2020 Targetting Combined Therapy to Cancer Stem Cells (NANOSTEM) IP: Simon Schwartz Navarro Collaborators: Laura García Latorre Funding agency: Instituto de Salud Carlos III Funding: 145540.01 Reference: PI11/01079 Duration: 01/01/2012 - 31/12/2014 Advancing on drug delivery-combined targeted treatments against human breast cancer and Leukemia (Oncotarget/Nano) IP: Simon Schwartz Navarro Collaborators: Ibane Abasolo Olaortua Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 28300 Reference: EUI2008-0170 Duration: 01/03/2009 - 01/03/2011 Pagination First page « Previous page ‹ … Page 4 Page 5 Current page 6 Page 7 Page 8 … Next page › Last page »
